Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel
NASDAQ:ALDX

Aldeyra Therapeutics Q3 2025 Earnings Report

Aldeyra Therapeutics logo
$1.72 -0.03 (-1.44%)
As of 12:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Aldeyra Therapeutics EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Aldeyra Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$24.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aldeyra Therapeutics Announcement Details

Quarter
Q3 2025
Date
11/5/2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Aldeyra Therapeutics' Q1 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, May 15, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Aldeyra Therapeutics' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Aldeyra Therapeutics Earnings Headlines

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines - ALDX
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-aldeyra-therapeutics-inc-of-class-action-lawsuit-and-upcoming-deadlines--aldx-302765117.html
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Misrepresented Clinical Trial Results: SueWallSt
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/aldx-investor-alert-aldeyra-therapeutics-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-company-allegedly-misrepresented-clinical-trial-results-suewallst-302765084.html
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines. But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.tc pixel
May 7 at 1:00 AM  |  Behind the Markets (Ad)
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
May 6 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3289151/9788/en/bronstein-gewirtz-grossman-llc-urges-aldeyra-therapeutics-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
May 6 at 11:22 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3289103/673/en/rosen-the-first-filing-firm-encourages-aldeyra-therapeutics-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-first-filed-by-the-firm-aldx.html
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Inconsistent Trial Data: Levi & Korsinsky
May 6 at 9:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/aldx-investor-alert-aldeyra-therapeutics-securities-fraud-lawsuit---investors-with-losses-may-seek-to-lead-the-class-action-after-company-allegedly-failed-to-disclose-inconsistent-trial-data-levi--korsinsky-302763727.html
See More Aldeyra Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aldeyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your email.

About Aldeyra Therapeutics

Aldeyra Therapeutics (NASDAQ:ALDX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis. Aldeyra is also developing ADX-2191, an intravitreal formulation targeting proliferative vitreoretinopathy, a serious complication of retinal detachment surgery. In addition to its ophthalmology pipeline, Aldeyra has earlier-stage programs exploring systemic indications where reactive aldehyde species contribute to inflammation and tissue damage.

Founded in 2009 and headquartered in Lexington, Massachusetts, Aldeyra is led by a management team with extensive experience in ophthalmology and biopharmaceutical development. Under the leadership of Chief Executive Officer Fredric A. Hargreaves, the company collaborates with clinical research centers across North America and Europe to advance its pipeline through late-stage clinical trials. Aldeyra’s strategy emphasizes rigorous clinical validation, strategic partnerships and readiness for commercial launch upon regulatory approval.

View Aldeyra Therapeutics Profile
Earnings Tools